Compare ALZN & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALZN | SOBR |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.3M |
| IPO Year | 2021 | 2008 |
| Metric | ALZN | SOBR |
|---|---|---|
| Price | $1.03 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | 54.4K | ★ 16.1M |
| Earning Date | 03-11-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.99 | ★ 103.55 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $437,421.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.62 |
| 52 Week Low | $0.84 | $0.48 |
| 52 Week High | $8.22 | $5.27 |
| Indicator | ALZN | SOBR |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 67.40 |
| Support Level | $1.03 | $1.28 |
| Resistance Level | $1.21 | $2.19 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 35.00 | 75.12 |
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.